Earnings Call · Q2 FY2023·2023-07-26

Q2 23EPS +5.00%·Rev n/aQ1 23EPS -4.17%·Rev n/aQ4 22EPS -13.04%·Rev n/aQ3 22EPS +8.70%·Rev n/a⚠ consensus missing

Viking Therapeutics, Inc. VKTX

Stephanie Diaz — Investor Relations

Brian Lian — President and CEO

Greg Zante — Chief Financial Officer

−1.4%1d on move date−1.5% vs SPY3d−0.3%5d−2.3%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more VKTX calls or request research access.

More VKTX calls Browse calls Request research access